Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK.
Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
Health Technol Assess. 2020 Mar;24(13):1-220. doi: 10.3310/hta24130.
New surgical approaches for apical prolapse have gradually been introduced, with few prospective randomised controlled trial data to evaluate their safety and efficacy compared with traditional methods.
To compare surgical uterine preservation with vaginal hysterectomy in women with uterine prolapse and abdominal procedures with vaginal procedures in women with vault prolapse in terms of clinical effectiveness, adverse events, quality of life and cost-effectiveness.
Two parallel randomised controlled trials (i.e. Uterine and Vault). Allocation was by remote web-based randomisation (1 : 1 ratio), minimised on the need for concomitant anterior and/or posterior procedure, concomitant incontinence procedure, age and surgeon.
UK hospitals.
Uterine trial - 563 out of 565 randomised women had uterine prolapse surgery. Vault trial - 208 out of 209 randomised women had vault prolapse surgery.
Uterine trial - uterine preservation or vaginal hysterectomy. Vault trial - abdominal or vaginal vault suspension.
The primary outcome measures were women's prolapse symptoms (as measured using the Pelvic Organ Prolapse Symptom Score), prolapse-specific quality of life and cost-effectiveness (as assessed by incremental cost per quality-adjusted life-year).
Uterine trial - adjusting for baseline and minimisation covariates, the mean Pelvic Organ Prolapse Symptom Score at 12 months for uterine preservation was 4.2 (standard deviation 4.9) versus vaginal hysterectomy with a Pelvic Organ Prolapse Symptom Score of 4.2 (standard deviation 5.3) (mean difference -0.05, 95% confidence interval -0.91 to 0.81). Serious adverse event rates were similar between the groups (uterine preservation 5.4% vs. vaginal hysterectomy 5.9%; risk ratio 0.82, 95% confidence interval 0.38 to 1.75). There was no difference in overall prolapse stage. Significantly more women would recommend vaginal hysterectomy to a friend (odds ratio 0.39, 95% confidence interval 0.18 to 0.83). Uterine preservation was £235 (95% confidence interval £6 to £464) more expensive than vaginal hysterectomy and generated non-significantly fewer quality-adjusted life-years (mean difference -0.004, 95% confidence interval -0.026 to 0.019). Vault trial - adjusting for baseline and minimisation covariates, the mean Pelvic Organ Prolapse Symptom Score at 12 months for an abdominal procedure was 5.6 (standard deviation 5.4) versus vaginal procedure with a Pelvic Organ Prolapse Symptom Score of 5.9 (standard deviation 5.4) (mean difference -0.61, 95% confidence interval -2.08 to 0.86). The serious adverse event rates were similar between the groups (abdominal 5.9% vs. vaginal 6.0%; risk ratio 0.97, 95% confidence interval 0.27 to 3.44). The objective anterior prolapse stage 2b or more was higher in the vaginal group than in the abdominal group (odds ratio 0.38, 95% confidence interval 0.18 to 0.79). There was no difference in the overall prolapse stage. An abdominal procedure was £570 (95% confidence interval £459 to £682) more expensive than a vaginal procedure and generated non-significantly more quality-adjusted life-years (mean difference 0.004, 95% confidence interval -0.031 to 0.041).
Uterine trial - in terms of efficacy, quality of life or adverse events in the short term, no difference was identified between uterine preservation and vaginal hysterectomy. Vault trial - in terms of efficacy, quality of life or adverse events in the short term, no difference was identified between an abdominal and a vaginal approach.
Long-term follow-up for at least 6 years is ongoing to identify recurrence rates, need for further prolapse surgery, adverse events and cost-effectiveness.
Current Controlled Trials ISRCTN86784244.
This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in ; Vol. 24, No. 13. See the National Institute for Health Research Journals Library website for further project information.
新的手术方法逐渐应用于 apical prolapse,与传统方法相比,很少有前瞻性随机对照试验数据来评估其安全性和有效性。
比较子宫保留与阴道子宫切除术治疗子宫脱垂,以及腹式与阴式手术治疗穹窿脱垂的临床疗效、不良事件、生活质量和成本效益。
两项平行的随机对照试验(即子宫和穹窿)。通过远程网络随机分配(1:1 比例),最小化同时需要前位和/或后位手术、同时需要治疗尿失禁、年龄和手术医生的需求。
英国医院。
子宫试验-563 名随机分配的女性中有 565 名接受了子宫脱垂手术。穹窿试验-208 名随机分配的女性中有 209 名接受了穹窿脱垂手术。
子宫试验-子宫保留或阴道子宫切除术。穹窿试验-腹部或阴道穹窿悬吊术。
主要结局指标为女性脱垂症状(采用盆腔器官脱垂症状评分测量)、脱垂特异性生活质量和成本效益(通过增量成本-每质量调整生命年评估)。
子宫试验-调整基线和最小化协变量后,子宫保留组 12 个月时的盆腔器官脱垂症状评分平均为 4.2(标准差 4.9),阴道子宫切除术组为 4.2(标准差 5.3)(平均差异-0.05,95%置信区间-0.91 至 0.81)。两组严重不良事件发生率相似(子宫保留组 5.4%比阴道子宫切除术组 5.9%;风险比 0.82,95%置信区间 0.38 至 1.75)。总体脱垂阶段无差异。阴道子宫切除术组中,更多的女性会向朋友推荐阴道子宫切除术(比值比 0.39,95%置信区间 0.18 至 0.83)。子宫保留比阴道子宫切除术昂贵 £235(95%置信区间 £6 至 £464),且产生的质量调整生命年非显著减少(平均差异-0.004,95%置信区间-0.026 至 0.019)。穹窿试验-调整基线和最小化协变量后,腹部手术组 12 个月时的盆腔器官脱垂症状评分平均为 5.6(标准差 5.4),阴道手术组为 5.9(标准差 5.4)(平均差异-0.61,95%置信区间-2.08 至 0.86)。两组严重不良事件发生率相似(腹部组 5.9%比阴道组 6.0%;风险比 0.97,95%置信区间 0.27 至 3.44)。阴道组的客观前位 2b 期或更高级别高于腹部组(比值比 0.38,95%置信区间 0.18 至 0.79)。总体脱垂阶段无差异。腹部手术比阴道手术昂贵 £570(95%置信区间 £459 至 £682),且产生的质量调整生命年非显著增加(平均差异 0.004,95%置信区间-0.031 至 0.041)。
子宫试验-就短期疗效、生活质量或不良事件而言,子宫保留与阴道子宫切除术之间无差异。穹窿试验-就短期疗效、生活质量或不良事件而言,腹部与阴道方法之间无差异。
正在进行至少 6 年的长期随访,以确定复发率、需要进一步的脱垂手术、不良事件和成本效益。
当前对照试验 ISRCTN86784244。
该项目由英国国家卫生研究院卫生技术评估计划资助,将在 ; 第 24 卷,第 13 期。有关该项目的更多信息,请访问英国国家卫生研究院期刊图书馆网站。